A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tolterodine (Detrol)

Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies (14) ] .

First FDA approval2014-01-21
Generic availableYes · 12 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$100.4M in CY2024 Part D spend1.2M claims · 387K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.206/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.212
Across all dosage forms in distribution.
Highest NADAC
$0.237
Range is tight.
Plans with PA
8 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Tolterodine used for?

Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies (14) ] .

Is there a generic for Tolterodine?

Yes. 26 ANDAs filed at FDA, 12 generic manufacturers currently shipping.

How much does my plan pay for Tolterodine?

Across 329 Part D plans, Tolterodine averages $0.212/unit (NADAC). Lowest available: $0.206/unit. Highest in distribution: $0.237/unit.

Is Tolterodine on the FDA shortage list?

No. Tolterodine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cholinergic Muscarinic Antagonist4 alternatives in D1
01
Darifenacin
Cholinergic Muscarinic Antagonist
$0.400Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Oxybutynin
Brand: OXYTROL
$0.032Lowest NADAC
21Generic mfrs
$174.7MCY24 Part D spend
Compare →
03
Solifenacin
Brand: VESIcare
$0.173Lowest NADAC
17Generic mfrs
$109.6MCY24 Part D spend
Compare →
04
Trospium
Cholinergic Muscarinic Antagonist
$0.234Lowest NADAC
10Generic mfrs
$72.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.